GO
Loading...

Biotechnology

More

  • Fish farming finds its way to land-locked Midwest Saturday, 13 Dec 2014 | 10:22 AM ET

    OMAHA, Neb.— The latest of five generations who have worked the same ground in northeastern Nebraska, 52- year-old Scott Garwood, isn't growing corn or cattle— it's fish. And such tank systems can be placed almost anywhere— from Minnesota to Florida— because temperature and water quality can be controlled. Globally, aquaculture supplies more than 50 percent of all...

  • Celgene CEO: Cancer drug pipeline booming  Monday, 8 Dec 2014 | 12:37 PM ET

    CNBC's Meg Tirrell speaks to Robert Hugin, Celgene chairman & CEO, about exciting new drugs emerging from Celgene's pipeline and the progress being made with Multiple myeloma.

  • Two biotechs to track now  Friday, 5 Dec 2014 | 5:23 PM ET

    Two stocks you need to watch ahead of San Francisco's 56th ASH hematology conference, with CNBC's Meg Tirrell.

  • RBC's biotech picks: CELG, BMRN & VRTX  Tuesday, 2 Dec 2014 | 5:18 PM ET

    Discussing some of the best stocks in the biotech industry going into 2015, with Michael Yee, RBC Capital Markets.

  • Biogen shows its hand  Tuesday, 2 Dec 2014 | 5:15 PM ET

    CNBC's Meg Tirrell provides insight to Biogen Idec's promising early study on its experimental medicine for Alzheimer's disease. Michael Yee, RBC Capital Markets, explains why the stock is headed higher from here.

  • Biogen's fight against Alzheimer's  Tuesday, 2 Dec 2014 | 2:19 PM ET

    Biogen's Alzheimer's drug has shown promise in studies, with CNBC's Meg Tirrell.

  • Banned in US, cleared in the UK  Monday, 1 Dec 2014 | 7:00 PM ET

    A Google-backed service to map DNA and identify potential risk factors for some diseases has been launched in the U.K., months after it was banned in the U.S..

  • Tracking the Allergan-Actavis merger  Monday, 17 Nov 2014 | 7:32 PM ET

    Sachin Shah, Analyst at Albert Fried and Company, discusses news that botox maker Allergan agreed to a $66 billion takeover bid from Actavis.

  • Geron sells last drug in pipeline to J&J unit Thursday, 13 Nov 2014 | 6:27 PM ET

    Nov 13- Geron Corp licensed its cancer compound, the last in its pipeline, to a unit of Johnson& Johnson for up to $935 million, sending its shares up as much as 33 percent in extended trading. The license deal comes as a welcome break to the company, which has seen its stock price drop from a high of $71.69 in 2000 to $2.31 on Thursday. If successful, imetelstat would...

  • Dendreon files bankruptcy protection  Monday, 10 Nov 2014 | 10:38 AM ET

    Prostate cancer drug developer Dendreon has filed for Chapter 11 bankruptcy protection. CNBC's Meg Tirrell takes a close look at what contributed to the company's downfall.

  • Integrating vets into corporate America: J&J CEO  Wednesday, 5 Nov 2014 | 2:30 PM ET

    CNBC's Meg Tirrell speaks to Alex Gorsky, Johnson & Johnson chairman & CEO, about helping military veterans transition from the battlefield into corporate America.

  • Arena Pharma's 'Belviq' potential  Monday, 3 Nov 2014 | 2:40 PM ET

    Jack Lief, Arena Pharmaceutical president & CEO, breaks down the company's Q3 earnings and discusses the outlook for its weight loss drug "Belviq."

  • Russia comes to Silicon Valley to recruit Monday, 3 Nov 2014 | 10:52 AM ET
    The Skolkovo Hypercube  in Moscow, Russia.

    Russia has a new tech city chock-full of co-working spaces, seed funding, and a research university. All they need now are the technologists.

  • TOKYO, Oct 30- Japan's Fujifilm Holdings Corp said it was difficult to estimate the profitability of its influenza drug Avigan, which has been earmarked to fight Ebola, given the uncertainty over the spread of virus, a company executive said on Thursday. France and Guinea plan to conduct clinical trials of Avigan 200 mg tablets, made by Fujifilm group company...

  • Bull case for biotech  Monday, 27 Oct 2014 | 11:25 AM ET

    CNBC's Bertha Coombs takes a close look at the wild swings taking place in the biotech sector.

  • Run up in biotech is highly rational: UBS  Wednesday, 22 Oct 2014 | 5:35 AM ET

    Matthew Roden, executive director of biotechnology equity research at UBS argued biotech stock valuations are still attractively valued even after their run higher.

  • Ebola stocks: Who's leading?  Wednesday, 1 Oct 2014 | 2:21 PM ET

    Discussing which biotech companies working on treatments for deadly viruses are the most investable, with Dr. Neil Shahrestani, Pura Vida analyst.

  • GMO 'superseeds' leading to 'superweeds' Tuesday, 30 Sep 2014 | 11:22 AM ET

    The newest batch of crop seeds is setting off another debate over GMOs. This time, they're being blamed for an infestation of "superweeds."

  • Cramer: Stay on biotech  Wednesday, 24 Sep 2014 | 8:51 AM ET

    CNBC's Jim Cramer takes a look at what's putting pressure on the markets and why he is watching the biotech sector.

  • ImClone's Waksal plans IPO  Wednesday, 24 Sep 2014 | 7:31 AM ET

    CNBC's Meg Tirrell reports Sam Waksal is back in the biotechnology industry.